Abiopharma

Incyte anuncia que se han aceptado más de 50 resúmenes para su presentación en la 2025 ASH Annual Meeting

Incyte annonce plus de 50 résumés acceptés pour présentation à lassemblée annuelle 2025 de lASH

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

FDA Issues Complete Response Letter for Biohavens VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

Pennant Acquires Senior Living Communities in Idaho and Wisconsin

Westlake kondigt openbaar bod in contanten aan

Westlake annonce une offre publique envisagée de billets de premier rang

FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation